FENC

Fennec Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

8.130

-0.07(-0.854%)1D

Line

Candle

YTD

High

8.320

Open

8.240

VWAP

8.11

Vol

45.01K

Mkt Cap

226.27M

Low

8.030

Amount

365.22K

EV/EBITDA(TTM)

Total Shares

27.32M

225.97M

EV/OCF(TTM)

P/S(TTM)

6.75

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

11.26M

+61.41%

-0.022

-89.52%

14.81M

+86.82%

0.100

-266.67%

14.98M

+71.15%

0.077

-291.68%

Estimates Revision

The market is revising Downward the revenue expectations for Fennec Pharmaceuticals Inc. (FENC) for FY2025, with the revenue forecasts being adjusted by -5.75% over the past three months. During the same period, the stock price has changed by -2.28%.

Revenue Estimates for FY2025

Revise Downward

-5.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-129.92%

In Past 3 Month

Stock Price

Go Down

-2.28%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 13.75 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.130

Low

13.00

Averages

13.75

High

15.00

Current: 8.130

Low

13.00

Averages

13.75

High

15.00

Craig-Hallum

Chase Knickerbocker

Buy

maintain

$13 -> $14

2025-08-15

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$13 -> $14

2025-08-15

maintain

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Fennec to $14 from $13 and keeps a Buy rating on the shares following quarterly results. The firm notes that legal expenses and one-time PSUs tied to 2025 goals drove elevated opex, but management expects material expense reduction in the second half of the year. Growth in the AYA population for Pedmark drove account expansion, with 14 new accounts added in the quarter. Internationally, Pedmarqsi launched in Germany and the U.K., with early royalty contributions from Norgine expected to ramp through the year. Additional EU launches are planned for the first half of 2026, and Japan data expected in Q4 bring potential partnership discussions for Japan rights and non-dilutive capital, Craig-Hallum adds.

Craig-Hallum

Buy

maintain

$12 -> $13

2025-05-14

Reason

Craig-Hallum

Price Target

$12 -> $13

2025-05-14

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Fennec to $13 from $12 and keeps a Buy rating on the shares following the company's Q1 earnings beat. The results for Q1 are near the breakeven amount for revenue, the firm notes. Craig-Hallum says that continued wins at potential major accounts, along with improved adherence to treatment from investments in the commercial team, could start to inflect the AYA channel.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$13

2025-03-11

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$13

2025-03-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$13

2024-12-17

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$13

2024-12-17

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Fennec Pharmaceuticals Inc (FENC.O) is 29.15, compared to its 5-year average forward P/E of 4.19. For a more detailed relative valuation and DCF analysis to assess Fennec Pharmaceuticals Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

4.19

Current PE

29.15

Overvalued PE

54.01

Undervalued PE

-45.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.73

Current EV/EBITDA

9.87

Overvalued EV/EBITDA

16.48

Undervalued EV/EBITDA

-9.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

18.42

Current PS

8.20

Overvalued PS

56.81

Undervalued PS

-19.98